Adagio Medical Holdings Files Q2 10-Q

TL;DR

Adagio Medical Holdings (formerly Aja Holdco) filed its Q2 10-Q, detailing fair value inputs like price volatility and expected term.

AI Summary

Adagio Medical Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Aja Holdco, Inc., changed its name on January 4, 2024. The filing details financial inputs related to fair value measurements, including price volatility, expected term, and exercise price for certain agreements.

Why It Matters

This filing provides insight into Adagio Medical Holdings' financial reporting and valuation methods for its assets and liabilities as of Q2 2024.

Risk Assessment

Risk Level: low — The filing is a standard quarterly report with no immediate red flags indicating high risk.

Key Players & Entities

• Adagio Medical Holdings, Inc. (company) — Filer of the 10-Q
• Aja Holdco, Inc. (company) — Former name of Adagio Medical Holdings, Inc.
• 20240630 (date) — End of the reporting period
• 20240104 (date) — Date of company name change

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ADGM The Nasdaq Stock Ma

Filing Documents

• tmb-20240630x10q.htm (10-Q) — 485KB
• tmb-20240630xex31d1.htm (EX-31.1) — 13KB
• tmb-20240630xex31d2.htm (EX-31.2) — 13KB
• tmb-20240630xex32d1.htm (EX-32.1) — 6KB
• tmb-20240630xex32d2.htm (EX-32.2) — 6KB
• 0001410578-24-001560.txt ( ) — 2435KB
• tmb-20240630.xsd (EX-101.SCH) — 28KB
• tmb-20240630_cal.xml (EX-101.CAL) — 7KB
• tmb-20240630_def.xml (EX-101.DEF) — 83KB
• tmb-20240630_lab.xml (EX-101.LAB) — 184KB
• tmb-20240630_pre.xml (EX-101.PRE) — 141KB
• tmb-20240630x10q_htm.xml (XML) — 259KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 1 Unaudited Condensed Statements of Operations for the Three and Six Months Ended June 30, 2024 2 Unaudited Condensed Statement of Changes in Stockholder's Deficit for the Three and Six Months Ended June 30, 2024 3 Unaudited Condensed Statement of Cash Flows for the Six Months Ended June 30, 2024 4 Notes to Unaudited Condensed Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 17 Item 4.

Controls and Procedures

Controls and Procedures 17

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 19 Item 1A.

Risk Factors

Risk Factors 19 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19 Item 3. Defaults Upon Senior Securities 19 Item 4. Mine Safety Disclosures 19 Item 5. Other Information 19 Item 6. Exhibits 20

SIGNATURES

SIGNATURES 22 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. ADAGIO MEDICAL HOLDINGS, INC. (known as Aja Holdco, Inc. during the periods reported) BALANCE SHEETS (UNAUDITED) June 30, December 31, 2024 2023 (Unaudited) Total Assets $ — $ — Liabilities and Stockholder's Deficit Liabilities Accrued expenses $ 5,000 $ 5,000 Total Liabilities 5,000 5,000 Stockholder's Deficit: Additional paid-in capital 2,134,199 — One share of Common Stock, $ 0.0001 par value; 1,000 shares authorized; 1 share issued and outstanding as of June 30, 2024 and December 31, 2023 — — Accumulated deficit ( 2,139,199 ) ( 5,000 ) Total stockholder's deficit ( 5,000 ) ( 5,000 ) Total Liabilities and Stockholder's Deficit $ — $ — The accompanying notes are an integral part of these financial statements. 1 Table of Contents ADAGIO MEDICAL HOLDINGS, INC. (known as Aja Holdco, Inc. during the periods reported) (UNAUDITED) For the Three For the Six Months Ended Months Ended June 30, 2024 June 30, 2024 General and administrative expenses $ — $ — Loss from operations — — Subscription Agreement expense ( 713,794 ) ( 2,134,199 ) Net loss $ ( 713,794 ) $ ( 2,134,199 ) Weighted-average shares outstanding, basic and diluted 1 1 Net loss per share of common stock, basic and diluted $ ( 713,794 ) $ ( 2,134,199 ) The accompanying notes are an integral part of these financial statements. 2 Table of Contents ADAGIO MEDICAL HOLDINGS, INC. (known as Aja Holdco, Inc. during the period reported) FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 (UNAUDITED) Additional Stock Paid-In Accumulated Stockholder's Shares Amount Capital Deficit Deficit Balance – December 31, 2023 1 $ — $ — $ ( 5,000 ) $ ( 5,000 ) Subscription Agreement expense — — 1,420,405 — 1,420,405 Net loss — — — ( 1,420,405 ) ( 1,420,405 ) Balance – M

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS JUNE 30, 2024 Note 1 - Description of Organization and Business Operations Aja HoldCo, Inc. (the "Company" or "ListCo") is a Delaware corporation, formed by Arya Sciences Acquisition Corp IV (the "Parent") on December 19, 2023 (inception). The Company has adopted a fiscal year end of December 31. The Company has no prior operating activities. On July 31, 2024, Adagio Medical, Inc. ("Adagio Medical")announced the closing of its previously announced business combination (the "Business Combination") with the Parent and the Company. In connection with the closing of the Business Comabination, the Company changed its name to "Adagio Medical Holdings, Inc." (see Note 4). Going Concern On July 31, 2024, the Company announced the closing of its previously announced Business Combination with the Company and Adagio Medical (see Note 4). As of July 31, 2024, substantial doubt about the Company's ability to continue as a going concern was alleviated due to the closing of the Business Combination. Note 2 - Summary of Significant Accounting Policies Basis of Presentation The financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Emerging Growth Company The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in

View Full Filing

View this 10-Q filing on SEC EDGAR